18:08 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammatory disease Cell culture and mouse studies identified two analogs of tozasertib, a tool compound pan-aurora kinase inhibitor, that could help treat systemic inflammatory response syndrome (SIRS). Chemical synthesis of tozasertib analogs and testing in...
17:35 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

APTO-253: Development delayed

Aptose said it will “temporarily delay clinical activities” for its IV APTO-253 to allow the company to investigate the cause of manufacturing issues. Aptose said it will prioritize its resources on preclinical cancer candidate CG026806...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Company News

CrystalGenomics, Aptose Biosciences deal

CrystalGenomics granted Aptose an exclusive option to license rights to CG026806 outside of China and Korea. CrystalGenomics will receive an upfront payment of $1 million and is eligible for a $2 million option exercise...
02:43 , Jun 9, 2016 |  BC Extra  |  Company News

Aptose, CrystalGenomics in deal for multi-kinase inhibitor

CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to CG026806 outside of China and Korea. The compound is a small molecule inhibitor of Bruton's tyrosine kinase (Btk), FMS-like...
08:00 , Nov 20, 2014 |  BC Innovations  |  Cover Story

Tapping TOPK

Although targeting proteins involved in cell division is falling out of fashion in cancer research because of the difficulty of distinguishing between diseased and normal cells, several companies are still exploring enzymes that could be...
08:00 , Jan 30, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Amgen's IBD gene hunt Amgen Inc. is teaming up with researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard to find new targets in inflammatory bowel disease. The partners hope an unbiased...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

ACT Biotech, Eddingpharm deal

Eddingpharm acquired exclusive, worldwide rights to develop and commercialize oncology compounds telatinib, ACTB1003 and ACTB1010 from ACT Biotech. Eddingpharm said the deal includes "several hundred" compounds from the same family as the three...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

Sareum, Hebei Medical University Biomedical Engineering Center deal

Sareum granted Hebei Medical University Biomedical Engineering Center (HMUBEC) exclusive rights in China, including Hong Kong and Macau, and Taiwan to develop and commercialize Sareum's inhibitor of aurora kinases and FMS-like tyrosine kinase...
08:00 , Nov 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Aurora kinases; polo-like kinase 1 (PLK1; STPK13) Mouse and cell culture studies suggest inhibiting aurora...
08:00 , Nov 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Aurora kinase B (AURKB; aurora-B) In vitro and mouse studies identified an AURKB-specific inhibitor that could...